Prialt Approval History
FDA Approved: Yes (First approved December 28, 2004)
Brand name: Prialt
Generic name: ziconotide
Dosage form: Intrathecal Infusion
Company: Elan Corporation, plc
Treatment for: Pain
Prialt (ziconotide) is a non-opioid intrathecal (IT) therapy indicated for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or IT morphine.
Development History and FDA Approval Process for Prialt
|Dec 28, 2004||Prialt Elan Corporation, plc - Treatment for Severe Chronic Pain|
|Jun 28, 2004||Elan Files Amendment to New Drug Application for Prialt for Severe Chronic Pain Based on Additional Efficacy and Safety Data|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.